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Objective: A novel approach to regulate obesity-associated adipose inflammation may be through metabolic reprogramming of macrophages
(MFs). Broadly speaking, MFs dependent on glucose are pro-inflammatory, classically activated MFs (CAM), which contribute to adipose
inflammation and insulin resistance. In contrast, MFs that primarily metabolize fatty acids are alternatively activated MFs (AAM) and maintain
tissue insulin sensitivity. In actuality, there is much flexibility and overlap in the CAM-AAM spectrum in vivo dependent upon various stimuli in the
microenvironment. We hypothesized that specific lipid trafficking proteins, e.g. fatty acid transport protein 1 (FATP1), would direct MF fatty acid
transport and metabolism to limit inflammation and contribute to the maintenance of adipose tissue homeostasis.
Methods: Bone marrow derived MFs (BMDMs) from Fatp1/ and Fatp1þ/þ mice were used to investigate FATP1-dependent substrate
metabolism, bioenergetics, metabolomics, and inflammatory responses. We also generated C57BL/6J chimeric mice by bone marrow transplant
specifically lacking hematopoetic FATP1 (Fatp1B/) and controls Fatp1Bþ/þ. Mice were challenged by high fat diet (HFD) or low fat diet (LFD) and
analyses including MRI, glucose and insulin tolerance tests, flow cytometric, histologic, and protein quantification assays were conducted. Finally,
an FATP1-overexpressing RAW 264.7 MF cell line (FATP1-OE) and empty vector control (FATP1-EV) were developed as a gain of function model
to test effects on substrate metabolism, bioenergetics, metabolomics, and inflammatory responses.
Results: Fatp1 is downregulated with pro-inflammatory stimulation of MFs. Fatp1/ BMDMs and FATP1-OE RAW 264.7 MFs demonstrated
that FATP1 reciprocally controled metabolic flexibility, i.e. lipid and glucose metabolism, which was associated with inflammatory response.
Supporting our previous work demonstrating the positive relationship between glucose metabolism and inflammation, loss of FATP1 enhanced
glucose metabolism and exaggerated the pro-inflammatory CAM phenotype. Fatp1B/ chimeras fed a HFD gained more epididymal white
adipose mass, which was inflamed and oxidatively stressed, compared to HFD-fed Fatp1Bþ/þ controls. Adipose tissue macrophages displayed a
CAM-like phenotype in the absence of Fatp1. Conversely, functional overexpression of FATP1 decreased many aspects of glucose metabolism
and diminished CAM-stimulated inflammation in vitro. FATP1 displayed acyl-CoA synthetase activity for long chain fatty acids in MFs and
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Conclusion: Our findings provide evidence that FATP1 is a novel regulator of MF activation through control of substrate metabolism. Absence of
FATP1 exacerbated pro-inflammatory activation in vitro and increased local and systemic components of the metabolic syndrome in HFD-fed
Fatp1B/ mice. In contrast, gain of FATP1 activity in MFs suggested that Fatp1-mediated activation of fatty acids, substrate switch to
glucose, oxidative stress, and lipid mediator synthesis are potential mechanisms. We demonstrate for the first time that FATP1 provides a unique
mechanism by which the inflammatory tone of adipose and systemic metabolism may be regulated.
 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Chronic over-nutrition results in low-grade inflammation in metaboli-
cally sensitive tissues that contributes to systemic metabolic dysre-
gulation. In obese individuals, as much as 40% of total body
composition is adipose. Adipose tissue MFs (ATMs) may account for
up to 50% of the cellularity in the obese adipose microenvironment
compared to just 10e20% in non-obese [1,2], demonstrating that
ATMs play a central role in shaping the adipose inflammatory milieu.
Indeed, ATMs are the primary source of inflammatory cytokines such
as tumor necrosis factor alpha (TNF-a) and interleukin 6 (IL-6) in
adipose tissue, and, thus, perpetuate obesity-associated inflammation
and subsequent comorbidities. Adipose inflammation in obesity has
been linked to insulin resistance, type 2 diabetes, cardiovascular
disease, and cancer [3,4]. Understanding the etiology of metabolic
associated inflammation is critical for combating metabolic diseases.
Dramatic changes within the adipose microenvironment occur with the
onset and progression of obesity, including an influx of monocytes [5].
Initial studies in the early 2000s described dichotomous ATM pheno-
types, either pro- or anti-inflammatory [6]. Several models suggested
that monocytes differentiate into pro-inflammatory, or “classically
activated” MFs (CAM), in response to the conditions encountered
within the obese adipose microenvironment. Persistent CAM activation
is purported to sustain adipose inflammation, eventually leading toMOLECULAR METABOLISM 5 (2016) 506e526  2016 The Authors. Published by Elsevier GmbH. This is an op
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MFs (AAM), also termed “alternatively activated”, are recognized to
maintain tissue homeostasis, including insulin sensitivity, by sup-
porting remodeling and secretion of anti-inflammatory cytokines [4].
In vitro, CAMs are modeled by activation of the so-called “M1” clas-
sical pathway upon exposure to type 1 T-helper cytokines [9]. In
contrast, AAMs are activated to the “M2” phenotype by exposure to
type 2 T-helper cytokines in vitro [6]. Recent evidence also has sug-
gested that in both obesity and weight loss, ATMs can be “metaboli-
cally” activated and direct lipid trafficking, thus buffering against the
excessive free fatty acid concentrations resulting from enhanced
lipolysis in adipose [10e12]. These MFs are characterized by
expression of both CAM- and AAM-associated surface markers,
enhanced lysosome biogenesis, expression of PPARg responsive
genes and inhibited autophagy [10,11].
As appreciation of the complexity of the ATM inflammatory phenotype
has evolved, so has understanding of the metabolic signature asso-
ciated with ATMs [13e15]. We and others have demonstrated that
CAMs exhibit a significant up-regulation of glucose metabolism,
particularly flux through the pentose phosphate pathway (PPP) to
generate reactive oxygen species (ROS) [16e19]. We reported that
pro-inflammatory activation is achievable by enhancing glucose
metabolism via glucose transporter 1 (GLUT1) overexpression using an
in vitro model, even in the absence of external stimuli [20], in aen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 507
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metabolic reprogramming and activation state. As second messen-
gers, ROS drive production of inflammatory enzymes, cytokines, and
chemokines such as inducible nitric oxide synthase (iNOS), TNF-a,
monocyte chemoattractant protein-1 (MCP-1) and IL-6 [4,16]. Overall,
when considering metabolic phenotype of MFs, CAMs are primarily
glucose-dependent. In contrast, lysosomal lipolysis and fatty acid
oxidative metabolism is necessary to generate AAMs [11,12,18,21],
although other CPT1-mediated functions may also be important [22]. In
a clear link between the immune response and metabolism, iNOS
production of nitric oxide (NO) is a key mediator promoting the
glycolytic/pro-inflammatory phenotype of MFs and blunting the anti-
inflammatory phenotype through NO’s role in inhibiting the electron
transport chain associated with oxidative metabolism in AAM [23].
Thus, it is clear that while our understanding of MF markers, function
and immune response has increased, the complexity of metabolism in
regulating MF biology e especially in changing in vivo microenvi-
ronments e remains uncertain.
Metabolic reprogramming of MFs offers a novel means of regulating
inflammation, hence we hypothesized that metabolism of fatty acids by
specific lipid trafficking proteins plays a critical role in suppressing
ATM-mediated inflammation and maintaining glucose tolerance. Fatty
acid transport protein 1 (FATP1, SLC27A1) is an ideal candidate for
limiting pro-inflammatory activation: FATP1 is an acyl-CoA synthetase
with affinity for long and very long chain fatty acids [24] e lending
specificity to its function e which is important because some MF fatty
acid transporters, such as CD36, are promiscuous [21,25]. FATP1
expression levels are highest in tissues characterized by active fatty
acid uptake and lipid metabolism, such as adipose, heart, and skeletal
muscle and is primarily localized to the plasma membrane, mito-
chondria, and peroxisomes [26e28]. In adipocytes, FATP1 activity is
regulated by insulin-mediated translocation that increases fatty acid
uptake [29]. Studies of total-body Fatp1 knockout mice demonstrated
that loss of FATP1 protected mice from the effects of HFD-induced
obesity, insulin resistance, and intramuscular lipid accumulation
[29,30]. Functional characterization of FATP1 and activation of fatty
acids through its ACSL activity have been conducted in these tissues
and cell types, but, to date, not in MFs [29e34]. Due to its complex
expression pattern, the contribution of FATP1 to the development of
insulin resistance is likely to be tissue- and cell-type specific. In silico
analysis of existing Immunological Genome “ImmGen” Project
expression data suggested that Fatp1 is detected in MFs and plas-
macytoid dendritic cells [35], but not other cells that may contribute to
inflammation including monocytes, microglia, B cells, T cells, neu-
trophils, and eosinophils.
Herein, we report that FATP1 plays a critical role in suppressing
inflammation in vitro and reducing MF infiltration and inflammation
in vivo through modulation of lipid mediators and oxidative stress. We
demonstrate for the first time that FATP1 provides a unique mecha-
nism by which the metabolic and inflammatory tone of adipose and
systemic metabolism may be regulated.
2. MATERIALS AND METHODS
2.1. Reagents
All reagents were obtained from SigmaeAldrich (St. Louis, MO) unless
otherwise noted. IFNg and IL-4 were obtained from R&D Systems
(Minneapolis, MN). Lipopolysaccharide (LPS, Sigma E. coli L4391) was
diluted in sterile PBS at a final concentration of 1 mg/mL. Novolin
human insulin was purchased from Novo Nordisk (Plainsboro, NJ).
Antibodies were purchased from the following sources: F4/80 (AbD508 MOLECULAR METABOLISM 5 (2016) 506e526  2016 The Authors. Published by Elsevier GmbH. TSerotec/BioRad, Hercules, CA); CD16/32 (Fc Block, BioLegend, San
Diego, CA), CD45-FITC, F4/80-PE, Ly6G/C-PE-Cy7, CD11b-APC,
CD11c-APC-eFluor 780, CD11c-eFluor 450, CD206-APC (eBioscience,
San Diego, CA), PhosphoAKT-Ser473 and total AKT (Cell Signaling
Technology), and insulin (H-86; Santa Cruz Biotechnology, Inc., Santa
Cruz, CA).
2.2. Animals and diets
Animal studies were performed with approval and in accordance with
the guidelines of the Institutional Animal Care and Use Committee at
the University of North Carolina at Chapel Hill. Animals were cared for
according to the recommendations of the Panel on Euthanasia of the
American Veterinary Medical Association. The veterinary care provided
at UNC is in compliance with the Public Health Service Policy on Hu-
mane Care and Use of Laboratory Animals and meets the National
Institutes of Health standards as set forth in the Guide for the Care and
Use of Laboratory Animals (DHHS Publication No. (NIH) 85-23 Revised
1985). The animal facility is Association for Assessment and Accred-
itation of Laboratory Animal Care (AAALAC) approved and is respon-
sible for the health and husbandry of animals. UNC also accepts as
mandatory the PHS Policy on Humane Care and Use of Laboratory
Animals be Awardee Institutions and NIH Principles for the Utilization
and Care of Vertebrate Animals Used in Testing, Research, and
Training. Animal studies comply with the ARRIVE guidelines. Mice were
housed in a climate controlled Department of Laboratory Animal
Medicine facility with a 12-hour light:dark cycle and ad libitum access
to food and water. Fatp1/ mice [30] were backcrossed >12 gen-
erations to the C57BL/6J genetic background. Fatp1 total body
knockout (Fatp1/) and Fatp1 wild type (Fatp1þ/þ) bone marrow
donor mice were generated using Fatp1/þ breeding pairs to generate
littermate controls.
2.3. Adipose tissue MFs
To isolate ATMs from lean and obese adipose, male C57BL/6J mice
were randomized onto either chow or an obesogenic diet (HFD, 45%
kcal from fat, HFD; D06011802, Research Diets, New Brunswick, NJ)
at weaning. After 23 weeks on diet, epididymal white adipose tissue
(eWAT) was minced in 25 mM HEPES-buffered DMEM/1% fatty acid-
free, low endotoxin BSA (Sigma) and completely digested with 0.5 mg/
mL Liberase TM (Roche Diagnostics, Indianapolis, IN) at 37. Samples
were centrifuged at 200 g for 10 min at 4 to pellet the MF-rich
stroma vascular fraction (SVF). The pellet was washed twice with in
25 mM HEPES-buffered DMEM/1% fatty acid-free, low endotoxin BSA
and red blood cells were lysed and washed again. Samples were
stained with anti-F4/80-PE and sorted on a MoFlo cell sorter (Beckman
Coulter, Brea, CA). F4/80hi MFs were collected for mRNA isolation and
gene expression analysis.
2.4. Fatp1 genotyping
Genomic DNA was isolated from tail biopsies, eWAT, and BMDM using
a DNeasy Blood and Tissue kit (Qiagen, Valencia, CA). Genotyping was
performed using the following primers: Fatp1 forward: GGCGGT
CAATGTTAAGTAAACTGG, Fatp1þ/þ reverse: CTCACACCACCCTGCAA-
GACTCT, Fatp1/ neomycin cassette reverse: GTAATGGGATAGGT
CACGTTGGTG [30]. iProof High-Fidelity PCR super mix (Bio-Rad, Her-
cules, CA)-based genotyping was performed on a C1000 thermocycler
(Bio-Rad, Hercules, CA).
2.5. BMDM isolation, differentiation, and activation
Bone marrow was collected from chow-fed gender- and age-matched
male Fatp1þ/þ and Fatp1/ mice. Marrow was cultured in RPMI-his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1640 containing 30% L929 conditioned media supplemented with
10% FBS, 2 mM glutamine, 100 IU/mL penicillin and 100 mg/mL
streptomycin (SigmaeAldrich, St. Louis, MO). For bioenergetics as-
says, BMDM were differentiated using M-CSF (20 ng/ml). BMDM were
left as naïve unstimulated MFs (Un), or activated using 5 ng/mL LPS
and 10 ng/mL IFNg (CAM) or 10 ng/mL IL-4 (AAM) for 24 h [18]. Cell
densities and viability were determined by hematocytometer and try-
pan blue exclusion, respectively. Cell size, volume, and viability were
determined using a Sceptor handheld automated cell counter (Mil-
lipore, Billerica, MA).
2.6. Immunoblot
FATP1 protein expression was measured by immunoblotting as pre-
viously described [36]. Polyclonal anti-sera raised against the C-ter-
minus of FATP1 or antibody against b-tubulin diluted 1:1000 in PBS
with 0.1% Tween-20, overnight was used. Primary antibodies were
detected with LI-COR secondary antibodies and imaged on the LI-COR
Odyssey Imaging System (Lincoln, NE). PhosphoAKT (ser473) and total
AKT was measured by immunoblotting as previously described [37].
2.7. Long chain acyl-CoA synthetase (ACSL) activity assay
Total ACSL activity was measured as previously described [38]. 14C-
Oleate acid (PerkinElmer Life Sciences, Akron, OH) was incubated with
cell homogenate and reactions were terminated after 10 min. Heptane-
washed aqueous phase (0.6 mL) was counted on a Wallac 1409 Liquid
scintillation counter (PerkinElmer Life Science, Waltham, MA). Total
ACSL activity was expressed as nanomoles of oleate-CoA ester
formed/minute/mg protein.
2.8. Metabolomics and eicosanoid profiling
Fatp1þ/þ and Fatp1/ BMDM or FATP1-EV and FATP1-OE RAW264.7
were plated on low binding, non-tissue culture treated plates. 24 h
after plating, both RAW MFs and BMDM were left untreated (Un) or
activated to CAM as above. Analysis of AAM-stimulated MFs at
Metabolon were cost prohibitive at the time of this study. PBS-washed
cells were detached by scraping, flash frozen in liquid nitrogen, and
metabolomics analysis on lysates was completed by Metabolon, Inc.
(Research Triangle Park, NC) [39]. N¼ 4 replicates per group. Missing
values were imputed with the minimum. Data are presented as relative
measures of “scaled intensity” after normalization to protein and
median scaling to 1. For measurement of eWAT 8-iso-PGF2a and cell
media eicosanoids, lipids were extracted from 25 mg of pulverized
eWAT tissue and eicosanoids were quantified by liquid chromatog-
raphy with an Agilent 1200 Series capillary HPLC (Agilent Technolo-
gies, Santa Clara, CA, USA) as previously described [40]. Negative ion
electrospray ionization tandem mass spectrometry was used for
detection. N ¼ 8 per group for eWAT and N ¼ 4 for cell media from
Fatp1þ/þ and Fatp1/ BMDM or FATP1-EV and FATP1-OE
RAW264.7.
2.9. High fat diet study
MF Fatp1þ/þ (Fatp1bonemarrowþ/þ, Fatp1Bþ/þ) and deficient (Fatp1B/)
chimeric mice were generated using bone marrow transplant (BMT)
strategy as outlined in supplemental Figure appendix (“A”) A5 B. Briefly,
3-week-oldmale C57BL/6J recipient micewere purchased from Jackson
Laboratories (Bar Harbor, ME). Upon arrival, C57BL/6J mice were ran-
domized to either a purified low fat diet (10% kcal from fat, LFD;
D07010502, Research Diets, New Brunswick, NJ) or HFD. At 6 weeks of
age, recipient mice were administered 2 doses of X-ray radiation
(500 cGy  2, spaced 4 h apart; X-RAD, North Branford, CT). Simulta-
neously, bone marrow was harvested from 6 week old male Fatp1/MOLECULAR METABOLISM 5 (2016) 506e526  2016 The Authors. Published by Elsevier GmbH. This is an op
www.molecularmetabolism.comand Fatp1þ/þ donor micemaintained on standard chow and transplanted
as in Makowski et al. [41]. Control irradiated animals that were not
reconstituted with bone marrow died within 10 days of irradiation.
Fatp1Bþ/þand Fatp1B/ chimeric animals were maintained on LFD or
HFD for a total of 23 weeks. N ¼ 16e17 mice per diet group and
genotype.
2.10. Metabolic phenotyping
Body composition was measured immediately prior to BMT and prior
to sacrifice (at 23 weeks on diet) using magnetic resonance imaging
(MRI, EchoMRI, Houston, TX). Blood glucose was measured at 3
weeks on the diets and again at termination, both following a 6 h
fast. Randomly fed blood glucose was measured at 9:00 AM after 23
weeks on diet. Intraperitoneal glucose tolerance tests (GTT) and in-
sulin tolerance tests (ITT) were performed at weeks 19 and 20 on
diet, following 6 or 4 h fast, respectively [42]. Briefly, 2.0 gm/kg body
weight of glucose or 0.75U of insulin was injected intraperitoneally,
and blood glucose was measured over 120 min. All blood glucose
measurements were performed using a FreeStyle Freedom Lite
glucometer (Abbot Diabetes Care, Inc., Alameda, CA). Plasma insulin
was measured by ELISA (EMD Millipore, Billerica, MA). Fasting
glucose (mg/dL) and insulin (pmol/L) concentrations measured just
prior to euthanasia were used to calculate HOMAIR and HOMA%B [43].
N ¼ 5 mice were injected with insulin (0.75 U) prior to euthanasia in
6 h fasted mice to determine insulin sensitivity by Western
Immunoblot.
2.11. Tissue and blood collection
Animals were euthanized with tribromoethanol/amylene hydrate
(1.25%, Sigma Aldrich, St. Louis, MO). Blood was collected via cardiac
puncture and plasma was separated from other blood components by
centrifugation at 200 g for 5 min at 4 C. eWAT and pancreata were
collected and fixed in 10% formalin for histological analyses. A portion
of eWAT tissue was flash frozen and pulverized in liquid nitrogen for
Western immunoblot.
2.12. Hematologic analysis
Hematologic analysis was conducted on fed 10-week-old Fatp1þ/þ
and Fatp1/ age-matched male and female mice maintained on ad
libitum chow. Blood was collected by submandibular bleed into EDTA-
coated tubes. Hematologic analysis occurred in the UNC Mouse Clinical
Chemistry Core using an automated hematology analyzer. In addition,
flow cytometry was used to enumerate circulating leukocyte pop-
ulations. Blood was collected from samples for hematologic analysis,
and red blood cells were lysed in ACK lysis buffer. Cells were washed
twice in HBSS, resuspended in PBS, counted, and then 1  105 cells
were stained with CD45-FITC, F4/80-PE, Ly6G/C-PE-Cy7, CD11b-APC,
CD11c-APC-eFluor 780 in the presence of anti-CD16/32 (Fc block) in
FACS buffer (1% FBS in PBS) as described in Murphy et al. [44].
Samples were analyzed on the Dako CyAN ADP flow cytometer
(Beckman Coulter, Inc., Fullerton, CA) and FlowJo Software (TreeStar,
Ashland, OR). Gating strategy is included as supplemental Figure A1.
2.13. Quantitation of secreted cytokines and chemokines
Concentrations of plasma leptin, IL-6, TNFa, and MCP-1 or conditioned
media IL-1b, IL-6, Il-10, and MCP-1 were measured using a MAGPIX
Luminex kit (EMD Millipore, Billerica, MA).
2.14. Gene expression analysis
Total mRNA was isolated from eWAT and cultured cells using an
RNeasy kit (Qiagen, Valencia, CA). RNA quantity and quality wasen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 509
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reverse transcribed using the iScript cDNA synthesis kit (Bio-Rad,
Hercules, CA). Gene expression was quantitated by qPCR using Assay-
On-Demand chemistries on an ABI 7900HT machine (Life Technolo-
gies, Grand Island, NY) [45]. Expression levels of genes of interest were
normalized to expression of 18S. Animals whose body weight was at or
above the mean body weight for the experimental group were selected
for analysis; therefore, unless indicated, N ¼ 8e9/group for mouse
data and N ¼ 3e6 experiments for cell culture studies.
2.15. Morphological and immunohistochemical analyses of eWAT
and pancreata
Anti-F4/80 and 4-HNE immunohistochemistry staining was conducted
as previously described [46]. Pancreatic islets of Langerhans were
visualized by H&E [46,47]. All histological sections were scanned on an
Aperio ScanScope CS Ultra-Resolution Digital Scanner and analyzed
using ScanScope Image Analysis Toolbox software (Buffalo Grove, IL)
[37].
2.16. FATP1-OE stable MF cell line generation and
characterization
The DNA sequence for Fatp1was obtained from the National Institutes of
Health Mammalian Gene Collection. Fatp1 cDNA containing a 50 EcoRI
site followed by a Kozak sequence and Flag tag and a 30 NotI site was
cloned into the pCI-neo Mammalian Expression vector (Promega, Mad-
ison, WI). The upstream primer: 50-GATCGAATTCGCCACCATGGATTACA-
AGGATGACGACGATAAGCGGGCTCCTGGAGCAGGAACAGCC-3’. The down
stream primer: 50-GATCGCGGCCGCTCAGAGTGAGAAGTCGCCTGC-3’.
Sequencing confirmed the fidelity of the sequence. Mouse
RAW264.7 MV cells (ATCC, Manassas, VA; ATCC# TIB-71) were
transfected with either the empty vector (FATP1-EV) or FATP1 expression
construct (FATP1-OE) using the AMAXA Nucleofector V kit (Lonza, Co-
logne, Germany). Stable cell lines were established and diluted serially to
obtain clonal isolates under selection using 400 mg/ml G418 Sulfate
(Cellgro, Manassas, VA) for 2 weeks. All transfected MFs were subse-
quently maintained in 200 mg/mL G418 Sulfate. RAW264.7 FATP1-EV
and FATP1-OE cells were grown in Dulbecco’s minimal essential me-
dia (DMEM) 4.5 g/L glucose supplemented with 10% FBS, 100 IU/mL
penicillin and 100 mg/mL streptomycin (SigmaeAldrich, St. Louis, MO).
Studies reported herein were repeated in a second set of clones and the
parent heterologous population of FATP-EV and FATP1-OE from which
the clones were isolated (data not shown). Cell viability, size and volume
were determined as above. Cell proliferation was determined by 3-(4, 5-
dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay
(ATCC) over 24e96 h of culture [20].
2.17. Substrate uptake and metabolism
FATP1-EV and FATP1-OE RAW264.7, or Fatp1þ/þ and Fatp1/
BMDM were plated at 1.5  105 or 7.5  105 cells/well, respectively,
into 24 well plates, allowed to attach overnight and stimulated as
above. Cells were washed with PBS and then incubated untreated or
with 2 mM BODIPY C16 fluorescent palmitic acid (Molecular Probe,
Grand Island, NY) in DMEM for 30 min at 37 C [48]. Fluorescence was
measured using a CyAn ADP Analyzer flow cytometer (Beckman
Coulter, Fullerton, CA) and FlowJo software (TreeStar, Ashland, OR)
[49]. To measure fatty acid oxidation, 1.0 mCi/mL BSA-conjugated 1-
[14C]-oleic acid (PerkinElmer Life Sciences, Waltham, MA) was added
to DMEM containing 12.5 mM HEPES, 1 mM L-carnitine to a final
concentration of 0.5%, 100 mM sodium oleate. 14C-CO2 was captured
and counted using EcoScint H. Glucose uptake, oxidation and glycogen510 MOLECULAR METABOLISM 5 (2016) 506e526  2016 The Authors. Published by Elsevier GmbH. Tsynthesis were measured as previously described [20]. Results were
normalized to protein concentration.
2.18. Cellular bioenergetics
FATP1-EV or FATP1-OE RAW MVs (6  104/well) were seeded into a
Seahorse Bioscience (Billerica, MA) tissue culture plate, allowed to
attach for 3 h and activated with 100 ng/mL LPS (RAW264.7) or PBS
vehicle control. Fatp1þ/þ or Fatp1/ BMDMs (2  105/well) were
seeded and allowed to attach for 3 h and then either left as naïve
unstimulated MFs (Un), CAM, or AAM activated for 24 h as above.
Prior to analysis, cells were washed twice with DMEM (RAW) or RPMI
(BMDM) assay media (sodium bicarbonate- and glucose-free DMEM or
RPMI supplemented with 2 mM glutamine, 100 IU/mL penicillin and
100 mg/mL streptomycin (SigmaeAldrich, St. Louis, MO) and equili-
brated for 1 h at 37 C without CO2. Measures of glycolytic rate and
glycolytic capacity were determined by recording extracellular acidi-
fication rates (ECAR, mpH/min) and oxygen consumption rates (OCR,
pmol/min) on a Seahorse Bioscience XF24 Extracellular Flux Analyzer
(Billerica, MA) [50]. The injection of glucose was used to measure
glycolytic rate (final concentration 25 mM (RAW) or 11 mM (BMDM);
Sigma, St. Louis, MO). Oligomycin was injected to measure glycolytic
capacity (final concentration 2.5 mM; Sigma, St. Louis, MO). 2-
deoxyglucose was used to blunt glycolysis (final concentration
20 mM). N ¼ 6 replicates per genotype/treatment. Equal plating
density was confirmed by protein assay. Experiments were repeated a
minimum of three times.
2.19. Human gene expression, variants, and trait association
To determine whether human genetic variants may act as cis-regu-
lators of FATP1 expression, we searched for expression quantitative
trait loci (eQTLs) for FATP1 (SLC27A1) located within 1 Mb of the
coding sequence. We searched the Multiple Tissue Human Expression
Resource (MuTHER) study of HapMap-imputed variants associated
with gene expression in subcutaneous adipose tissue from 856 female
twins [51] available in the Genvar database [51]. We used the same
criteria to look up cis-eQTLs in subcutaneous adipose expression data
from the METabolic Syndrome In Men (METSIM) study of 1000
Genomes-imputed variants in 1381 men [52]. Expression levels were
analyzed after adjustment for 40 inferred determinants from factor
analysis [53].
2.20. Statistics
For body weight data analyses, a regression model was run with
genotype/diet group and week (0 thru 23) as predictors. To account for
the repeated measures over time within animals an autoregressive
within-subject correlation matrix was fit. F-tests using the resulting
parameter and standard error estimates were constructed to make
comparisons of interest. Analyses were performed using SAS Version
9.3 (SAS Institute, Cary NC). Robust pairwise correlations were
determined using Spearman Correlation, utilizing pairwise complete
observations when missing data was present. We utilized the “cor.t-
est” function in R to obtain exact p-values testing whether the
observed correlations were significantly different from 0. PCA plot was
made using ArrayStudio (OmicSoft, Cary, NC). For all other in vivo,
ex vivo or in vitro data, statistical differences between experimental
groups were determined by two-way ANOVA followed by multiple
comparisons tests using statistical software within GraphPad Prism
(GraphPad Software, Inc., La Jolla, CA). For ex vivo and in vitro ex-
periments, representative results are reported; at least N ¼ 3 exper-
iments were conducted with N ¼ 3e6 replicates per assay. All datahis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1: Fatp1 deletion decreased MF acyl-CoA synthetase (ACSL) activity and resulted in a metabolic shift from lipid oxidation to glycolysis that resulted in
exacerbated CAM and reduced AAM activation. A. Fatp1-Fatp6 mRNA was measured in BMDM generated from Fatp1þ/þ and Fatp1/ mice on chow diet (n.d., not detected.
**P < 0.01; ****P < 0.0001 Fatp1þ/þ vs. Fatp1/). B. FATP1 protein expression was measured by Western immunoblot in unstimulated BMDM. Tubulin is used as a loading
control. C. ACSL activity was measured using 14Ceoleate in unstimulated Fatp1þ/þ and Fatp1/ BMDMs (*P < 0.05). D. Oxygen consumption rate (OCR) was measured using the
Seahorse Extracellular Flux Analyzer in Un, CAM, and AAM activated BMDM from Fatp1þ/þ and Fatp1/ mice. (***P < 0.001). E. Fatty acid uptake was measured using BODIPY-
palmitate (*P < 0.05 and ****P < 0.0001, Fatp1þ/þ vs. Fatp1/). F. Complete fatty acid oxidation was measured using 14C-oleate (*P < 0.0001). G. Glucose transporter 1 (Glut1)
mRNA was quantified by qPCR (****P < 0.0001). H. Glycolytic rate, as measured by extracellular acidification rate (ECAR), was measured using the Seahorse Extracellular Flux
Analyzer (*P < 0.05, ***P < 0.001). I. Inducible nitric oxide synthase (Nos2), Arginase-1 (J) and Hmox-1 (K) mRNA expression levels were measured by qPCR (*P < 0.05 and
***P < 0.001); activation has an effect in all figures (P < 0.0001). Data are mean  SEM; differences were detected by two-way ANOVA. Representative of at least N ¼ 3
experiments with n ¼ 4 replicates per experiment. Metabolites including (L) Riboflavin (Vitamin B2) and (M) eicosanoid 15-HETE were quantified (*P < 0.05; **P < 0.01,
***P < 0.001 Fatp1þ/þ vs. Fatp1/ and P^ < 0.001 or P^ < 0.0001 for diet effect, N ¼ 4.).
MOLECULAR METABOLISM 5 (2016) 506e526  2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Original articleare shown as mean standard error of the mean (SEM). P values less
than 0.05 were considered statistically significant.
3. RESULTS
3.1. Lack of FATP1 induced a metabolic substrate switch from fatty
acid to glucose metabolism
We hypothesized that FATP1 plays a role in supporting MF function
and inflammation by directing lipid metabolism in MFs. To test this
hypothesis using a common in vitromodel to study MF biology, BMDM
were isolated and differentiated from age-matched, chow-fed male
Fatp1þ/þ and Fatp1/ mice. There were no differences in the
number or gross morphology of BMDM generated from Fatp1/ mice
compared to Fatp1þ/þ mice (data not shown). Figure 1 A shows that in
Fatp1þ/þ BMDM, Fatp1 expression was 2-fold higher in AAM
compared to CAM-stimulated BMDMs, replicating in silico findings
[54]. Fatp1 expression was reduced (P < 0.001) in Fatp1/ BMDM,
as expected [30]. Fatp2, 3, and 5 were undetected. Relative to Fatp1,
BMDMs express Fatp4 at higher concentrations in all activation states.
In contrast to Fatp1, Fatp4 expression is increased 3-fold in CAM
activated compared to unstimulated and AAM-stimulated BMDM. No
compensation for Fatp1 deficiency by Fatp4 or Fatp6 was detected; in
fact, in CAM-stimulated BMDM, Fatp4 was detected at lower levels in
Fatp1/ compared to Fatp1þ/þ BMDM (P < 0.0001, Figure 1A).
Minor non-translated Fatp1 mRNA was detected due to where qPCR
primers were located. The lack of FATP1 protein (Figure 1B) and a 40%
reduction in total ACSL BMDM enzymatic activity (P< 0.01, Figure 1C)
had no effect on the size or viability of BMDMs (Figure A2 AeB).
To examine effects of lack of FATP1 on MF metabolism, we next
examined cellular bioenergetics, fatty acid uptake, and substrate
metabolism. Mitochondrial oxidative phosphorylation, as measured by
oxygen consumption rate (OCR), was elevated in AAMs compared to
unstimulated or CAMs, as expected [18]. OCR was significantly higher
in Fatp1/ compared to Fatp1þ/þ BMDM in all activation states
(P < 0.001, Figure 1D). In Fatp1þ/þ BMDM, AAM-activation induced a
57% and 97% increase in fatty acid internalization when compared to
unstimulated (P < 0.0001) or CAM, respectively (P < 0.001,
Figure 1E). Compared to Fatp1þ/þ, fatty acid uptake was reduced by
21% and 24% in unstimulated (P < 0.05) and AAM-activated Fatp1/
 BMDM (P < 0.0001), respectively. The diminished fatty acid uptake
in AAM-activated Fatp1/ BMDM correlated with a 17% reduction in
complete oleate oxidation compared to Fatp1þ/þ controls
(P < 0.0001, Figure 1F). There were no significant differences in
incomplete fatty acid oxidation as measured by 14C incorporation into
acid soluble metabolites (data not shown).
Because MVs markedly enhance glucose metabolism when CAM
activated, we determined if inhibition of lipid metabolism via deletion of
FATP1 would reprogram BMDM metabolism toward increased glucose
usage, thus creating a CAM-like metabolic phenotype. Expression of
glucose transporter 1 (Glut1) was significantly increased in CAM
activated Fatp1/ compared to Fatp1þ/þ BMDM (P < 0.0001,
Figure 1G). Next, extracellular acidification rate (ECAR) was used to
measure glycolytic rate. Fatp1/ BMDM displayed significantly
increased glycolytic rates in unstimulated (P < 0.05), CAM-
(P< 0.001) and AAM-activated (P< 0.05) states compared to Fatp1þ/
þ BMDM (Figure 1H). Glycolytic capacity was similarly elevated in the
absence of FATP1 (Figure A2 C). Neither glucose oxidation or glycogen
synthesis was affected by Fatp1 genotype (data not shown). Spearman
correlation analyses revealed a significant inverse correlation between
glycolytic rate and fatty acid oxidation (r ¼ 0.63, P ¼ 3  104).
Furthermore, both glycolytic rate (r ¼ 0.77, P ¼ 0.0053) and512 MOLECULAR METABOLISM 5 (2016) 506e526  2016 The Authors. Published by Elsevier GmbH. Tcapacity (r ¼ 0.89, P ¼ 1  104) were inversely proportional to
ACSL activity.
3.2. Lack of FATP1 primed MVs for exaggerated pro-inflammatory
response upon CAM activation and hindered activation to the AAM
phenotype
Expanding on our observations that Fatp1/ BMDM internalized and
oxidized less fatty acid compared to Fatp1þ/þ, together with existing
evidence linking MF substrate metabolism and inflammatory pheno-
type [16,18,20], we next measured the basal expression and inflam-
matory response of Fatp1þ/þ and Fatp1/ BMDMs. Expression of the
classic CAM marker inducible nitric oxide synthase (Nos2) was 2-fold
higher in Fatp1/ compared to Fatp1þ/þ CAM-activated BMDMs
(P < 0.0001, Figure 1I). AAM marker Arginase-1 (Arg1) [18] up-
regulation was significantly blunted in Fatp1/ compared to
Fatp1þ/þ BMDM (P< 0.05, Figure 1J). Furthermore, heme oxygenase
e 1 (Hmox-1) expression, an anti-inflammatory marker [55,56], was
reduced by 50% in both CAM- and AAM-activated Fatp1/ BMDM
(P < 0.001, Figure 1K). Antigen presenting molecules were also
evaluated in BMDM. CD86 and CD80, two molecules that prime T cells,
were increased by CAM activation, but regulation was not altered by
Fatp1 (supplemental Figure A3 AeB). HLA class II histocompatibility
antigen gamma chain, or CD74, was increased by both CAM and AAM
activation, but Fatp1 did not alter expression significantly
(supplemental Figure A3 C).
3.3. Metabolomic analysis of Fatp1/ BMDM indicated enhanced
glucose metabolism, particularly through the PPP
To further test FATP1’s effects on substrate metabolism, compre-
hensive metabolomics profiling was undertaken. Fatp1þ/þ and
Fatp1/ BMDM were isolated, left unstimulated or CAM activated,
and then lysed for metabolite analysis. CAM activation increased 54
and 49 metabolites and downregulated 123 and 115 metabolites in
Fatp1þ/þ and Fatp1/, respectively. As expected, carbohydrate
metabolism was upregulated with CAM activation of BMDMs regard-
less of genotype from the unstimulated state especially “Fructose,
mannose, galactose, starch, and sucrose metabolism”, “Nucleotide
sugars, pentose metabolism”, and most of the metabolites from
glycolysis and the Krebs cycle. However, some metabolites were
downregulated with CAM activation including glucose, fumarate, and
malate, among others (Table A1, and P values within). Several path-
ways were also downregulated when BMDMs were CAM activated
from the unstimulated state, including the “glycine, serine and thre-
onine metabolism” subpathway, several nucleotides, other amino acid
metabolism, dipeptides, and gamma-glutamyl amino acid metabolites.
Likewise, most of the cofactor and vitamins were downregulated with
the exception of biopterin and two nicotinate and nicotinamide me-
tabolites. There was little regulation of fatty acid metabolism except a
decrease in the essential fatty acids docosapentaenoate (n6 DPA;
22:5n6), docosahexaenoate (DHA; 22:6n3), and medium chain fatty
acid caproate (6:0) with CAM activation. Increased concentrations of
metabolites in glycerolipid metabolism, some lysolipids, and prosta-
glandinse with a tremendous 40þ-fold increase in PGD2e with CAM
stimulation in both genotypes were detected.
We next compared Fatp1-directed differences between BMDMs
(Table A1, and P values within). Metabolic changes in BMDMs were
predominantly driven by CAM activation with overlapping variability in
Fatp1/ compared to Fatp1þ/þ, as demonstrated by principal
component analysis (PCA) plot in supplemental Figure A4. There were
a total of 11 metabolites upregulated and 13 downregulated in Fatp1/
 compared to Fatp1þ/þ in the inactivated state (P < 0.05). Whenhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 2: Deletion of MF Fatp1 increased susceptibility to HFD-induced weight gain, glucose intolerance, and increased epididymal white fat mass. A. Body weights
were measured weekly (Fatp1B/ vs. Fatp1Bþ/þ mice on HFD; ***P < 0.001). B. Randomly fed blood glucose was measured at 23 weeks on diet (*P < 0.05). C. Intraperitoneal
glucose tolerance tests were conducted at 19 weeks on diet after a 6hr fast. HFD-fed Fatp1Bþ/þ vs. Fatp1B/ (**P < 0.01 and *P < 0.05). D. Epididymal white fat mass was
quantified at sacrifice. In HFD-fed mice, **P < 0.01 in Fatp1Bþ/þ vs. Fatp1B/ mice. Data are means  SEM; all differences detected by two-way ANOVA, except for panel “A”;
N ¼ 16e17 mice per group which was analyzed by mixed regression modeling.BMDM were CAM activated, there were 12 upregulated and 13
downregulated in Fatp1/ compared to Fatp1þ/þ. Fatp1/ in both
unstimulated and CAM activated states had greater concentrations of
metabolites including glutamate, hypotaurine, taurine, N-acetylneur-
aminate, and the medium chain fatty acid pelargonate (9:0). Signifi-
cantly lower concentrations of some metabolites in the pathways
entitled “Fructose, mannose, galactose, starch, and sucrose meta-
bolism”, “Glycolysis, gluconeogenesis, pyruvate metabolism” and
“Glycine, serine and threonine metabolism” were detected. For
example, significantly lower concentrations of sorbitol, glucose,
glycine, serine, and asparagine were detected in Fatp1/ in both
unstimulated and CAM activated states compared to Fatp1þ/þ. 22%
less intracellular lactate was detected in Fatp1/ BMDM compared to
Fatp1þ/þ in the CAM-stimulated state. Fatp1/ displayed signifi-
cantly less ethanolamine in the unstimulated state compared to
Fatp1þ/þ (P < 0.05), but concentrations between Fatp1þ/þ and
Fatp1/ were identical in CAM. Riboflavin (or Vitamin B2) was another
metabolite that was significantly 1.97-fold greater in Fatp1/
compared to Fatp1þ/þ BMDM in the unstimulated state (P < 0.05,
Figure 1L) but was significantly lower (0.27-fold or 73% less) in
Fatp1/ BMDMs compared to Fatp1þ/þ BMDM in the CAM-activated
state (P< 0.01, Figure 1L). Glycerophosphorylcholine (GPC) was 0.81-
fold lower in Fatp1/ BMDMs in the unstimulated state (P< 0.0001);
however, upon CAM activation, Fatp1/ BMDMs contained 1.20-fold
(P < 0.001) greater GPC compared to Fatp1þ/þ in respective states.
Finally, eicosanoids were detected in media from the same BMDMMOLECULAR METABOLISM 5 (2016) 506e526  2016 The Authors. Published by Elsevier GmbH. This is an op
www.molecularmetabolism.comexperiment where metabolites in lysates were measured (Table A3).
One of the most strikingly regulated eicosanoids was 15-
Hydroxyicosatetraenoic acid (15-HETE), which was significantly upre-
gulated in unstimulated and CAM activated Fatp1/ compared to
Fatp1þ/þ BMDM (P < 0.0001 for both states, Figure 1M and
Table A3). Other arachidonic acid metabolites including 12-HETE and
5-HETE as well as linoleic acid metabolite 9,10-Dihydroxy-12Z-octa-
decenoate (9,10-di-HOME) were also significantly increased in Fatp1/
 compared to Fatp1þ/þ BMDM (P < 0.05, Table A3).
3.4. A lack of MF FATP1 exacerbated HFD-induced weight gain
and induced glucose intolerance and greater accretion of epididymal
white adipose tissue (eWAT)
Because Fatp1 regulated substrate metabolism and directed MF
activation in vitro, we sought to test effects of loss of function in vivo.
We first demonstrated that Fatp1 mRNA was elevated 7.5-fold in F4/
80 þ ATMs isolated from the stromovascular fraction from obese
eWAT compared to lean mice at 23 weeks of age (Figure A5 A,
P < 0.001). Based on the fact that Fatp1 is expressed in obese ATMs
and may play a role in MF lipid metabolism and inflammation, we next
created chimeras to study Fatp1 deficiency in ATM function. Male
C57BL/6J recipient mice were randomized onto either LFD or HFD at 3
weeks of age so mice would remain lean or gain weight, respectively.
After 3 weeks on the diets (i.e., at 6 weeks of age), fasting glucose and
MRI-determined body composition were identical for all mice regard-
less of diet group (data not shown). At this time point, recipient miceen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 513
Figure 3: Lack of MF FATP1 increased adipose inflammation, shifted ATM phenotype, increased inflammasome expression and oxidative stress in HFD-fed mice. Ae
D. F4/80þ MF staining was conducted in eWAT. Representative 10X images are presented. E. Quantification of crown like structures (CLS, arrows in D) in eWAT in 5 random 20X
fields (P < 0.01 in Fatp1Bþ/þ vs. Fatp1B/-). F. mRNA expression of MF markers Emr1 (F4/80), Cd11b and Cd11c was measured by qPCR in eWAT (**P < 0.01 and *P < 0.05
Fatp1Bþ/þ vs. Fatp1B/ within the same diet group). G. Flow cytometric analysis of % F4/80 þ CD11c-eFluor450 and % F4/80 þ CD206-APC positive staining in Fatp1Bþ/þ and
Fatp1B/ ATMs cells isolated from eWAT stromovascular fraction from eWAT from Fatp1Bþ/þ and Fatp1B/ mice fed HFD for 23 weeks (N ¼ 3). Il-6 (H) and Il-1b (I) mRNA
expression was measured by qPCR (**P < 0.01,*P < 0.05). J. Inflammasome mRNA expression in eWAT was measured by qPCR (**P < 0.01). K. Oxidative damage was assessed
by 8-iso-PGF2a concentration (*P < 0.05). Data shown are means  SEM; differences detected by two-way ANOVA; N ¼ 7e9 mice per group.
Original articlewere lethally irradiated and transplanted with bone marrow from
Fatp1þ/þ and Fatp1/ donor mice to generate chimeric mice
harboring either Fatp1bonemarrowþ/þ (FATP1Bþ/þ) or Fatp1bonemarrow/
 (Fatp1B/) (see study design cartoon in Figure A5 B). Control mice
that were irradiated but did not receive marrow died within 10 days of
irradiation (data not shown). To confirm successful ablation and
reconstitution of Fatp1-deficient marrow, BMDM were isolated from a
cohort of LFD-fed and HFD-fed Fatp1Bþ/þ and Fatp1B/ mice. There
were no significant differences in number or appearance of BMDM
isolated from the transplanted and diet-exposed mice (data not
shown). Figure A5 C illustrates that the irradiation and reconstitution
with Fatp1þ/þ or Fatp1/ marrow was successful as only the
mutated Fatp1 null allele, not wildtype Fatp1, was detectable in BMDM
isolated from mice transplanted with Fatp1/ bone marrow. Gene
expression (not shown) and immunoblot analysis of these BMDM
demonstrated that FATP1 was successfully ablated from MFs in this514 MOLECULAR METABOLISM 5 (2016) 506e526  2016 The Authors. Published by Elsevier GmbH. Tmodel (Figure A5 D). In addition, hematologic and flow cytometric
analysis of Fatp1þ/þ and Fatp1/ mice demonstrated no significant
differences in any measure including white blood cells, lymphocytes,
granulocytes, monocytes, by either total numbers of cells or per-
centage of cells within the total blood cell population (Table A4 and A5).
After irradiation and reconstitution, Fatp1B/ mice gained signifi-
cantly more weight compared to Fatp1Bþ/þ on HFD (P < 0.0001 from
15 weeks through to sacrifice at 23 weeks on diet) (Figure 2A). After 23
weeks on diet, random-fed blood glucose concentrations were 14%
higher in Fatp1B/ mice compared to Fatp1Bþ/þ on HFD (P < 0.05,
Figure 2B). Six-hour-fasted blood glucose concentrations did not differ
significantly by genotype; LFD-fed Fatp1Bþ/þ, and Fatp1B/ fasted
blood glucose concentrations at termination were an average of
133 mg/dL for both genotypes, whereas HFD-fed concentrations were
131.5 and 147 mg/dL, respectively. Six-hour-fasted plasma insulin
concentrations at termination revealed no significant differenceshis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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among the groups (supplemental Figure A6 A). Likewise, there were no
differences in homeostasis model assessment of insulin resistance
(HOMAIR) or homeostasis model % b cell function (HOMA%b) (data not
shown).
Glucose tolerance tests (GTT) were performed to evaluate systemic
metabolic responses in Fatp1Bþ/þ and Fatp1B/ LFD- and HFD-fed
mice. Overall, HFD in this BMT model did not induce dramatic de-
fects in glucose disposal, which was expected and similar to other
BMT models due to lack of extensive weight gain associated with
irradiation [42,57,58]. However, circulating glucose concentration at
15 min post glucose injection was significantly higher in Fatp1B/
mice on HFD (P < 0.001), which correlated to delayed and inefficient
disposal of glucose compared to Fatp1Bþ/þ for the remainder of the
time course (30 min: P ¼ 0.004; 60 min: P ¼ 0.03, 120 min:
P ¼ 0.04) (Figure 2C). Insulin tolerance tests (ITT) indicated that
neither diet nor genotype affected the glucose response to an injection
of insulin (supplemental Figure A6 B and C). Furthermore, histologic
and immunohistologic analysis of insulin staining and morphology of
islets in pancreata did not demonstrate significant alterations in
number or size of islets between diet and genotypes (supplemental
Figure A6 D). Finally, eWAT was analyzed in mice that received in-
sulin prior to sacrifice to determine insulin signaling capacity
(supplemental Figure A6 E). Quantification revealed that in LFD-fed
mice, regardless of genotype, insulin induced a 1.5e2-fold increase
in pAKT/AKT concentrations. There was no Fatp1 genotype effect;
however, insulin-stimulation reached significance in Fatp1Bþ/þ
(P ¼ 0.041) but failed to reach significance in Fatp1B/ LFD-fed
mice. In mice fed HFD, the insulin response was only 1-fold as
compared to 1.5e2-fold in lean mice. The insulin response was
statistically reduced in HFD-fed mice compared to LFD-mice in both
Fatp1Bþ/þ (P ¼ 0.0008) and Fatp1B/ (P ¼ 0.0008).
Body composition was next investigated to determine if MF FATP1
contributed to alterations in adipose tissue. Mice fed a HFD displayed
significantly increased percent body fat as measured by MRI as well as
elevated plasma leptin concentrations (P < 0.001, Figure A7 A and B,
respectively). A trend for Fatp1B/ mice to have greater adiposity and
leptin was evident, yet no significant genotype differences were
detected. However, isolated eWAT depots in HFD-fed Fatp1B/ mice
were 40% heavier compared to HFD-fed Fatp1Bþ/þ mice (P < 0.01,
Figure 3 D). Neither lean mass nor liver and brown adipose weights
were altered by genotype (Figure A7 CeE). Furthermore, no difference
was found in respiratory exchange rate (RER), measured by metabolic
chamber, during the day or at night between Fatp1B/ and Fatp1Bþ/þ
mice either on LFD or HFD despite a significant nighttime diet effect
(P ¼ 0.01) (Figure A7 F and G).
3.5. Deletion of MF Fatp1 led to augmented eWAT MF influx,
crown-like structure (CLS) formation, inflammation, activation of the
NLRP3 inflammasome, and oxidative damage in HFD-fed mice
Infiltration of MFs from transplanted marrow into eWAT was
confirmed by PCR-based genotyping of eWAT genomic DNA to detect
the mutated Fatp1 allele (Figure A7 H). There was a 60% increase in
the number of F4/80 þ CLS observed in eWAT from HFD-fed Fatp1B/
 mice compared to HFD-fed wild type controls (Figure 3AeD and
quantified in 3E, P < 0.01). Furthermore, qPCR gene expression
analysis for monocyte/MF markers Emr1 (F4/80), Cd11b, and Cd11c
indicated significant increases in HFD-associated MF influx in HFD-fed
Fatp1B/ eWAT compared to Fatp1Bþ/þ (2.7-fold higher, P < 0.01;
1.7 fold, P < 0.05; and 2.8-fold, P < 0.001, respectively, Figure 3F).
Importantly, flow cytometric analysis of F4/80 þ macrophages from
the SVF of eWAT demonstrated that more CAM-like CD11c þ CD206-MOLECULAR METABOLISM 5 (2016) 506e526  2016 The Authors. Published by Elsevier GmbH. This is an op
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Fatp1Bþ/þ on HFD. Likewise, a decrease in AAM-like CD11c-
CD206þ ATMS were present in eWAT from Fatp1B/ mice compared
to Fatp1Bþ/þ on HFD (Figure 3G, with gating strategy and scatter plots
in Figure A8 A and B respectively).
Upon the discovery of greater MF influx and a shift towards more
inflammatory ATM phenotype in Fatp1B/ mice compared to
Fatp1Bþ/þ on HFD, we next investigated pro-inflammatory cytokine
expression. Expression of the pro-inflammatory cytokine Il-6 was 5-
fold higher in eWAT from Fatp1B/ mice compared to Fatp1Bþ/þ
on HFD (P < 0.01, Figure 3H). Likewise, expression of the pro-
inflammatory cytokine Il-1b, was doubled in eWAT from Fatp1B/
mice compared to Fatp1Bþ/þ on HFD (P < 0.05, Figure 3I). IL-1b
production results from activation of the inflammasome [59]. We
observed significantly elevated expression of NLRP3 inflammasome
subunits including Nlrp3 and Pycard in eWAT from Fatp1B/ mice
compared to Fatp1Bþ/þ on HFD (P < 0.01, Figure 3J). Furthermore,
elevated 4-HNE (data not shown) and significantly increased concen-
trations of 8-iso-PGF2a, an indicator of non-enzymatic oxidative
damage, indicated increased oxidative damage in eWAT from HFD-fed
Fatp1B/ mice compared to HFD-fed Fatp1Bþ/þ mice (P < 0.05,
Figure 3K). Finally, there were trends for increased eicosanoids in LFD-
fed eWAT such as 15-HETE, 5-HETE and 9,10-DiHOME (metabolites
that were significantly regulated in BMDMs by Fatp1), however these
did not reach statistical significance in eWAT (data not shown).
3.6. FATP1 gain of function model drove ACSL activity and fatty
acid uptake
Given that lack of Fatp1 led to dramatic changes in vitro and in vivo, we
next determined if the highly glycolytic CAM-like RAW264.7 mouse
MF cell line could be metabolically reprogrammed toward an AAM-like
phenotype via FATP1 overexpression (FATP1-OE). First, expression
levels of the 6 members of the Fatp family were examined by qPCR.
RAW MFs expressed only Fatp1 and Fatp4, both of which were
induced 2-fold by 24 h LPS activation (Figure 4A). Fatp2, 3, 5, and 6
were not detected. Overexpression of both Fatp1 mRNA (P < 0.001,
Figure 4A) FATP1 protein in FATP1-OE was achieved compared to
empty vector controls (FATP1-EV, Figure 4B). FATP1 protein is
essentially undetected in unstimulated RAW MFs, thus FATP1 over-
expression created a gain of function model. A significant decrease in
Fatp4 expression in FATP1-OE MFs upon LPS activation was evident
compared to FATP1-EV (P < 0.05). FATP1 over expression had no
effect on cell size, viability, or growth (Figure A2 DeE).
ACSL activity assays were performed on FATP1-EV and FATP1-OE
MFs to ensure that the over-expressed FATP1 was functional. Total
ACSL activity was increased by 20% in FATP1-OE compared to FATP1-
EV (P < 0.05, Figure 4C). A 17% increase in fatty acid uptake was
detected in FATP1-OE compared to FATP1-EV in the unstimulated state
(P < 0.01, Figure 4D). LPS activation increased fatty acid uptake by
2.3-fold in FATP1-EV, while FATP1-OE showed a 2.7-fold increase.
Thus, fatty acid uptake in FATP1-OE was 36% greater than FATP1-EV
in LPS-stimulated cells (P < 0.0001, Figure 4D).
3.7. FATP1 overexpression reprograms RAW MFs toward an AAM-
like metabolic phenotype.
We next evaluated the capacity for metabolic flexibility in the RAW MF
cell line. There were no FATP1-mediated differences in either complete
or incomplete oleate oxidation (Figure A2 F and data not shown). LPS-
activation of RAW MF led to dramatically reduced complete fatty acid
oxidation regardless of FATP1 genotype, demonstrating a disconnect
between fatty acid uptake and oxidation (Figure 4D and A2 F). Aten access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 515
Figure 4: Overexpression of FATP1 in RAW264.7 MFs induced a substrate switch with enhanced lipid metabolism and reduced glucose metabolism resulting in
blunted CAM-activation. Fatp1 was stably over-expressed in RAW264.7 MFs (FATP1-OE) and controls were empty vector (FATP1-EV). A. Fatp1-6 were measured by qPCR (n.d.,
not detected; ***P < 0.001, *P < 0.05). B. FATP1 Western immunoblot in unstimulated RAW264.7 (RAW) MFs, FATP1-EV, and FATP1-OE. Tubulin was used as a loading control.
C. FATP1-mediated long chain ACSL activity was measured using 14Ceoleate (*P < 0.05). FATP1-EV and FATP1-OE were left untreated or stimulated for 24 h with 100 ng/ml LPS.
D. Fatty acid uptake was measured using BODIPY-palmitate (**P < 0.01, ***P < 0.001). E. Glut1 expression was measured by qPCR (**P < 0.01). Glycolytic rate (F) and
glycolytic capacity (G) were measured using a Seahorse Bioanalyzer (**P < 0.01, *P < 0.05). 14C-glucose oxidation (H) was measured (*P < 0.05). Data are mean  SEM.
Representative of at least N ¼ 3 experiments with n ¼ 4 replicates per experiment. mRNA expression was measured by qPCR for Nos2 (I) and Tnfa (J) and Hmox-1 (K)
(**P < 0.01, ***P < 0.001). Secreted IL-6 (L) and MCP-1 (M) and IL-1b (N) were measured by Luminex (**P < 0.01, *P < 0.05). Data are mean  SEM; differences were detected
by two-way ANOVA. Representative of at least N ¼ 3 experiments with n ¼ 4 replicates per experiment. O. Metabolite 9-HODE was measured in BMDM lysates (****P < 0.0001 for
both unstim and CAM FATP1-EV vs. FATP1-OE, N ¼ 4).
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baseline, there were no significant differences in Glut1 expression,
however with LPS stimulation Glut1 expression was 39% lower in
FATP1-OE compared to FATP1-EV (P< 0.01, Figure 4E). Acute glucose
uptake was reduced in FATP1-OE MVs, though this result did not
reach statistical significance (Figure A2 G). However, long-term bio-
energetics measurements demonstrated a significant 60% reduction in
glycolytic rate in FATP1-OE MFs compared to FATP1-EV controls in
both unstimulated and LPS-stimulated conditions (P < 0.01,
Figure 4F). Glycolytic capacity was also significantly reduced with
FATP1 overexpression to levels 60% of those in FATP1-EV (P < 0.05,
Figure 4G). In addition, FATP1-OE MFs demonstrated a 23% reduction
in glucose oxidation upon LPS-activation (P< 0.05, Figure 4H). Finally,
glycogen synthesis was unaffected by FATP1 expression in either
unstimulated or LPS-activated MFs (data not shown).
3.8. FATP1 gain of function inhibited MF pro-inflammatory
response
To examine the consequence of FATP1-mediated alterations in
metabolism on the inflammatory response in RAW MF, pro- and anti-
inflammatory mediators in unstimulated and LPS-stimulated cells were
examined. In direct contrast to expression patterns observed in
Fatp1/ BMDM, FATP1 overexpression significantly suppressed the
induction of LPS-induced pro-inflammatory enzyme Nos2 (P < 0.01,
Figure 4I) and cytokine Tnf-a (P < 0.01, Figure 4J). Hmox-1
expression was 2.3- and 2.8-fold higher in unstimulated and activated
FATP1-OE, respectively (Figure 4K). Secretion of IL-6 and MCP-1
protein was significantly diminished in response to LPS stimulation
in FATP1-OE compared to FATP1-EV (P < 0.01 and P < 0.05,
Figure 4L and M, respectively). IL-1b protein secretion was also
significantly reduced in FATP1-OE compared to FATP1-EV (P < 0.01,
Figure 4N). AAM-markersMrc-1 and Arginase-1 were not detectable in
FATP1-EV and FATP1-OE cells in either the unstimulated or LPS-
stimulated state.
3.9. Metabolomic and lipidomic analysis demonstrated that FATP1
overexpression down-regulated glucose metabolic pathways and
biomarkers of oxidative stress
Based on significant alterations to metabolism and inflammation, we
next used metabolomics and lipidomics to query potential mediators or
biomarkers associated with Fatp1. Metabolomic profiling revealed that
RAW264.7 MFs are highly metabolically active, especially in com-
parison with BMDM, because they are proliferating as an immortalized
cell line (Tables A1 and A2). In total, CAM activated upregulated 116 or
97 metabolites, with 25 or 56 downregulated in FATP1-EV or FATP1-
OE, respectively. In contrast to BMDM, RAW MFs that were CAM
stimulated greatly upregulated amino acid metabolism, did not
downregulate dipeptides, and greatly increased metabolites in car-
bohydrate metabolism and the Krebs cycle. CAM activated RAW MFs
also upregulated lipid metabolism including many fatty acid metabo-
lites, glycerolipids, and sphingolipids (but downregulated lysolipids).
RAW activation also increased pyridoxal metabolism, riboflavin meta-
bolism and thiamine metabolism, while BMDM did not regulate these
metabolites.
CAM stimulation of the RAW model altered the biochemical profiles of
FATP1-EV and FATP-OE along parallel but distinct trajectories
(supplemental Figure A4). Upon examining effects of FATP1 gain of
function on metabolites, FATP1 overexpression resulted in an up-
regulation of 40 and down-regulation of 73 metabolites in unstimu-
lated RAW cells, while CAM activation resulted in up-regulation of 38
and downregulation of 120 metabolites in FATP1-OE compared to
FATP1-EV (Table A2, and P values within). Regardless of activationMOLECULAR METABOLISM 5 (2016) 506e526  2016 The Authors. Published by Elsevier GmbH. This is an op
www.molecularmetabolism.comstate (unstimulated or CAM activated), examples of metabolites
significantly downregulated by FATP1-OE included glutamate and
glutamine, reduced glutathione (GSH), glucose, 3-phosphoglycerate,
PRPP, UDP-glucose, citrate, butyrlcarnitine, choline phosphate, pal-
mitoyl sphingomyelin and stearoyl sphinomelin, inosine, and AMP
(Table A2, and P values within, a subset are highlighted in pathway in
supplemental Figure A9 A). Examples of metabolites significantly
upregulated by FATP1-OE (regardless of activation state) include
pyroglutamine, gamma-aminobutyrate (GABA), imidazole propionate,
3-(4-hydroxyphenyl)lactate, 5 aminovalerate, 4-guaninobutanoate,
sorbitol, ribitol, 2-hydroxyglutarate, deoxycarnitine, 2-
dehydrocarnitine, acetylcarnitine, ethanolamine, choline, 5-
methyltetrahydrofolate, and riboflavin vitamin B2 (Table A2, and P
values within, and pathway supplemental Figure A9 A). Furthermore,
regardless of activation, several fatty acids were downregulated,
including essential fatty acids (docosapentaenoate (n3 DPA; 22:5n3),
docosapentaenoate (n6 DPA; 22:5n6), docosahexaenoate (DHA;
22:6n3)), stearate (18:0), arachidonate (20:4n6), and adrenate
(C22:4n6), reaching significance in CAM-stimulation for all fatty acids
listed, with the exception of adrenate, which reached significance in
both unstimulated and stimulated states. Of note, arachidonate
(20:4n6) was essentially undetectable in FATP1-OE after CAM stimu-
lation. Interestingly, not every long chain fatty acid was downregulated;
eicosenoate (20:1n9 or 11) and docosatrienoate (22:3n3) were upre-
gulated. Finally, intracellular lipid metabolite 9-hydroxy-10,12-
octadecadienoic acid (9-HODE) was essentially undetectable in
unstimulated cells but was significantly 3-fold increased in activated
FATP1-OE CAM stimulated cells (P¼ 0.0001 for FATP1-EV vs. FATP1-
OE, Figure 4O).
When cells were CAM activated compared to unstimulated, FATP1-EV
controls upregulated metabolites in the Krebs cycle including citrate,
succinate, fumarate, and malate, while FATP1-OE downregulated
these metabolites (Table A2, supplemental Figure A9 A). In contrast,
many lysolipids were upregulated with CAM stimulation in FATP1-OE
that were not regulated or downregulated in control EV cells,
including 1-palmitoylglycerophosphocholine, and 1-stearoylglycero-
phosphocholine. In line with radiotracer and bioenergetic data,
FATP1-OE demonstrated significant down-regulation of glucose in both
unstimulated and CAM-activated cells. PPP metabolites including
phosphoribosyl pyrophosphate (PRPP), 6-phosphogluconate, xanthine,
inosine, and UDP-glucuronate were at lower concentrations in CAM-
activated FATP1-OE compared to CAM-activated FATP1-EV controls
(Table A2, supplemental Figure A9 A).
One-carbon metabolism was also significantly altered with FATP1
overexpression in CAM. Concentrations of choline, betaine, glycer-
ophosphocholine and S-adenosylmethionine (SAM) were significantly
increased in CAM stimulated cells while metabolites downstream of
SAM were decreased, specifically methionine and cysteine in FATP1-
OE compared to FATP1-EV controls. Differences in B-vitamins were
observed with decreased pantothenate (B5) and increased riboflavin
(vitamin B2) in CAM stimulated cells with FATP1 overexpression.
Furthermore, a significant, greater than 2-fold, decrease in citrulline
concentration and a concomitant increase in polyamine spermidine
and polyamine-associated metabolite 5-methylthioadenosine (5-MTA)
in FATP1-OE upon CAM stimulation was detected (Table A2, and P
values within, pathway in supplemental Figure A9 B) [60]. Epigenetic
modification of macrophages is important [61,62]; FATP1 regulates
important methyl donors such as SAM (supplemental Figure A9 B).
Finally, significant reductions in markers of oxidative stress were
detected in FATP1-OE CAM activated cells compared to FATP1-EV
including methionine sulfoxide, cysteineglutathione disulfide, and 2-en access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 517
Original articleaminoadipate (supplemental Figure A10 AeC, P ¼ 0.01, 0.0001, and
0.0001, respectively).
3.10. FATP1 overexpression reduced free arachidonic acid and
certain eicosanoid synthesis
Because FATP1 is a long and very long chain ACS, we next investigated
long chain fatty acids including arachidonic and lineolate acid and
eicosanoid metabolism in our RAW control and gain of function model.
Significant alterations in arachidonate (20:4n6) were evident in FATP1-
OE lysates using metabolomic analysis with an 85% reduction when
FATP1 was over expressed (P < 0.05 FATP1-EV vs. FATP1-OE,
Figure 5A). Hence, we investigated eicosanoid metabolism in our RAW
control and gain of function model. Arachidonate metabolites includingFigure 5: Overexpression of FATP1 in RAW264.7 MFs decreased arachidonate and
lysates using metabolomics analysis (*P < 0.05 FATP1-EV vs. FATP1-OE) BeE. Eicosanoids
****P < 0.0001 FATP1-EV vs. FATP1-OE; P^ < 0.001 and P^ < 0.0001 unstimulated vs.
(****P < 0.0001).
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the media by overexpression of FATP1 (P < 0.0001 in both unsti-
mulated and CAM activated cells, Figure 5BeD). Linoleate (18:2n6)
was significantly upregulated by 50% in FATP1-OE in unstimulated cell
lysates (P < 0.05, Table A2) and non-significantly downregulated by
20% in CAM activated cells. When media was examined from the same
cells, FATP1-OE significantly downregulated linoleate metabolite 9,10-
diHOME (P < 0.0001, Figure 5E and Table A3).
3.11. FATP1 variants are associated with FATP1 expression levels
in human adipose
We searched public databases for genetic variants located within 1 Mb
of FATP1 that were associated with FATP1 expression (eQTLs) incertain eicosanoid concentrations. A. Arachidonate (20:4n6) was measured in cell
were measured in conditioned cell media. 15-HETE, 12-HETE and 5-HETE (**P < 0.01,
CAM). F. Linoleate metabolite 9,10-diHOME was measured in conditioned cell media
his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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human adipose tissue. The Multiple Tissue Human Expression
Resource (MuTHER) study of 856 female twins showed the strongest
eQTL for FATP1 with rs9137 (P¼ 1.3 1013), which is located in the
30UTR of FATP1. In the METabolic Syndromes In Men (METSIM) study
of 1,381 men, the strongest association with adipose FATP1 expres-
sion was observed for rs3212793 (P¼ 1.8 104), locatedw300 kb
downstream of the FATP1 gene. These results demonstrate that FATP1
levels vary between individuals and that these and/or other nearby
variants may be involved in the regulation of FATP1 expression.
4. DISCUSSION
Over the past 35 years, the prevalence of obesity has increased in both
Western nations and globally [63]. Immune-based therapies offer
promising interventions for obesity induced Type 2 Diabetes [64,65]
including several approaches aimed at increasing insulin sensitivity
by blocking the action of inflammatory mediators. Specifically, previ-
ous reports implicate IL-1a, IL-1b, TNFa, MCP-1 (CCL2), and IL-6
[64e70]. Our previous work demonstrated that modulating bioactive
lipid generation and trafficking in MFs is an effective tool against
obesity, insulin resistance, and diabetes [71e73]. Thus, we hypoth-
esized that maintaining sufficient lipid metabolism by modulating
transport and metabolism of specific fatty acids would suppress ATM-
mediated inflammation and preserve metabolic health. FATP1 is a fatty
transporter through its capacity to trap long and very long chain fatty
acids intracellularly via its ACSL activity. ACSL-mediated generation of
acyl-CoAs targets fatty acids to certain metabolic fates, which may
participate in the regulation of inflammation. Herein, to study FATP1 in
MF biology, complementary ex vivo BMDM loss-of-function and
in vitro RAW MF gain-of-function models as well as LFD- and HFD-
exposed mice were used to elucidate the metabolic and mechanistic
alterations stemming from modulation of Fatp1 expression.
BMDM and RAW MFs express only Fatp1 and Fatp4. No compensatory
expression of other Fatp gene family members was detected in
response to loss of FATP1. Therefore, total ACSL activity was signifi-
cantly reduced in Fatp1/ BMDM, demonstrating that while other
ACSLs are present to activate fatty acids, such as ACSL1 [74], there
was a lack of enzymatic compensation overall. Metabolic and bio-
energetics analysis of Fatp1/ BMDM demonstrated that along with
reduced ACSL activity, deletion of Fatp1 resulted in blunted fatty acid
uptake and oxidation, particularly in AAM-activated BMDMs, which are
established to be more fatty acid-dependent. Findings of reduced fatty
acid uptake and oxidation occurred even in the setting of elevated
oxygen consumption rate in Fatp1/ compared to Fatp1þ/þ BMDMs,
suggesting that there was no global defect in mitochondrial capacity. In
fact, anapleurotic substrates and BCAA were decreased in CAM-
activated Fatp1/ BMDM, which could have driven and sustained
the observed elevated mitochondrial respiration. Importantly, deletion
of Fatp1 reprogrammed MFs: a shift in metabolism toward increased
carbohydrate metabolism was detected. Notably, increased Glut1,
glycolysis and PPP metabolites were evident. Furthermore, both
glycolytic rate and capacity were inversely proportional to ACSL ac-
tivity. Less lactate was detected in Fatp1/ BMDMs, corroborating
the increase in extracellular lactate as measured by ECAR. Taken
together, greater OCR, ECAR, and glycolytic metabolites indicated that
Fatp1/ MFs have a higher energetic status compared to Fatp1þ/þ
MFs [75]. Deletion of Fatp1 fundamentally altered an aspect of
mitochondrial, biogenesis, function or activity of the electron transport
chain, perhaps uncoupling, which is under further investigation.
Spearman correlation analyses revealed a significant inverse correla-
tion between glycolytic rate and fatty acid oxidation, demonstrating theMOLECULAR METABOLISM 5 (2016) 506e526  2016 The Authors. Published by Elsevier GmbH. This is an op
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bility, in response to lack of Fatp1. The shift from fatty acid oxidation to
increased glycolysis appears to create a more CAM-like phenotype of
MF lacking Fatp1. Indeed, lack of Fatp1 resulted in increased Nos2
expression, a hallmark of CAM activation, as well as reduced Arginase-
1 expression, a classic AAM marker, and heme oxygenase 1, an anti-
inflammatory enzyme. CAM induction of iNOS and NO production leads
to NO-mediated downregulation of the electron transport chain,
providing a direct link between inflammation and metabolism [23]. In
sum, data suggest that while the lack of Fatp1 appears to activate
mitochondrial activity, specific defects in fatty acid uptake and
oxidation are linked to the inflammatory phenotype in the MF.
Since ex vivo BMDM studies were supportive of FATP1 reducing pro-
inflammatory activation of MF, the role of FATP1 in diet-induced
metabolic dysfunction was investigated next. Using a model of HFD-
induced weight gain, we investigated the contribution of MF FATP1
to inflammation and glucose tolerance. ATMs isolated from obese
adipose expressed greater Fatp1 than ATMs from lean mice,
demonstrating the relevance of this transporter to obesity-associated
MF function and lipid trafficking. Importantly, ATMs isolated from
mice fed HFD demonstrated that, in the absence of Fatp1, ATMs were
polarized towards CAM phenotype and less towards AAM. Thus, we
provide evidence that Fatp1B/ ATMs fail to maintain the AAM
phenotype and are skewed towards CAM compared to Fatp1Bþ/þ
ATMs, akin to in vitro loss of function BMDM studies. A detailed time
course would be ideal to understand Fatp1’s regulation on AAM and
CAM ATMs during obesogenesis.
In striking contrast to the total-body Fatp1/ mice [29,30], we report
that chimeric mice harboring MF that were deficient in Fatp1 were
more susceptible to diet-induced metabolic dysfunction including
greater weight gain and adiposity, hyperglycemia, and glucose intol-
erance compared to diet-matched Fatp1Bþ/þ mice. Impaired glucose
tolerance occurred in the setting of no Fatp1-mediated differences in
ITT, islet morphology, insulin signaling capacity, plasma insulin levels,
or calculated HOMA scores. It is possible that the discrepancy between
impaired glucose tolerance with no detectable impairment of ITT was
due to the timing of the GTT at 19 weeks, while the ITT and plasma
measures that occurred at sacrifice did not occur until 20 and 23
weeks on diet, respectively, when Fatp1-mediated effects may have
been lost. In the LFD-fed lean state, no significant Fatp1-mediated
effects were observed, demonstrating that HFD-induced stress was
necessary to observe the phenotype. Importantly, there were no sig-
nificant differences in circulating immune cell population numbers by
hematologic and flow cytometric analysis in cells isolated from whole
body Fatp1/mice compared to Fatp1þ/þ, demonstrating that FATP1
does not likely play a strong role in hematopoiesis. There were also no
differences in metabolic activity such as RER in LFD- or HFD-fed mice
in a Fatp1-dependent manner. Taken together, diet findings indicate
that MF FATP1 plays a specific role in limiting HFD-induced metabolic
dysfunction through local tissue homeostasis when deficiency is
restricted to MVs. The role of ACS activity in MF has been reported in
only one other model. Deletion of ACSL1 protected against the CAM
phenotype in diabetes and atherosclerosis [74]. Importantly, our
directly opposed findings in our chimeric model highlight the existence
of non-redundant roles for ACSLs within MFs.
A primary limitation to the project was that the chimera was created by
bone marrow transplantation, which inherently reduces the adipogenic
capacity of HFD exposure [42,57,58]. Therefore, while significant ef-
fects were detected in the absence of Fatp1 on HFD, the overall effect
of HFD on components of metabolic syndrome compared to LFD-fed
mice was limited. We acknowledge that our chosen study design ofen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 519
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differential between LFD- and HFD-fed wildtype-transplanted mice.
Still, wildtype-transplanted HFD-fed mice developed larger fat pads by
weight, greater fat mass by MRI, higher leptin, and had reduced RER,
as well as blunted insulin signaling by Western immunoblot. Perhaps if
a different diet, such as a sucrose-free LFD, a higher percent fat HFD,
or a different diet exposure time course were chosen, then there would
have been greater differences in weight gain and exaggerated FATP1-
mediated metabolic dysfunction. Our results beg the question of MF-
specific FATP1 effects, especially in an inducible manner. Thus, future
directions include studying FATP1-mediated effects specifically on
ATMs. Although in silico analysis using the ImmGen Project suggested
that FATP1 is only detected on MFs and plasmacytoid dendritic cells
[35], it is possible that T, B or other granulocytes could express Fatp1
at high levels in an obesity-dependent manner, which further supports
the need for additional studies using MF-specific Fatp1 over-
expression and deletion.
MV FATP1 may affect adipogenesis and systemic glucose metabolism
in several ways. First, Fatp1B/ mice fed a HFD accumulated excess
white adipose mass that was characterized by excessive CLS forma-
tion, MF infiltration, and inflammatory cytokine production. CLS are
classic histologic markers of adipose inflammation and obesity asso-
ciated with the metabolic syndrome [4]. Xu et al. have argued that
adipose tissue inflammation is influenced to a greater extent by sheer
MF number rather the phenotype of those MFs [11]. Herein, we report
an approximately 2-fold increase in MF marker expression, a 3-fold
increase of CLS, and an overall shift toward a CAM phenotype in the
absence of Fatp1 (represented by a doubling of Il-1b and 3.7-fold
higher Il-6 expression) in HFD-Fatp1B/ adipose tissue suggesting
that both MF number and ATM phenotype were affected by FATP1
expression. In addition, data support that FATP1 plays a role in limiting
both priming and activation of the NLRP3 inflammasome, which is an
established regulator of inflammation. Obesity activates the NLRP3
inflammasome, a nutrient sensor and potent regulator of the innate
immune system, leading to insulin resistance and diabetes [76]. The
NLRP3 inflammasome is activated by a “two-hit” process initiated by
many metabolites and other stimuli, thereby inducing CASPASE 1-
mediated cleavage of pro-IL-1b to active IL-1b [76]. Once secreted,
IL-1b induces production of cytokines and chemokines including IL-6,
IL-8, TNFa, and monocyte chemoattractant protein 1 (MCP-1, or
CCL2), which collectively promote further MF activation and migration
[70]. Transcription of the NLRP3 inflammasome components and its
product Il-1b was significantly increased in adipose from HFD-fed
Fatp1B/ compared to controls.
Oxidative stress is another hallmark of obesity. ROS are signaling
cascade second messengers known to enhance expression of pro-
inflammatory mediators. We and others have shown that persistent
activation of ROSegenerating pathways results in increased oxidative
damage [20,77,78]. Using targeted metabolomics and immunohisto-
chemistry, we detected increased adipose oxidative damage in HFD-
fed Fatp1B/ mice with reductions in small molecule biomarkers of
oxidative stress including methionine sulfoxide, cysteineglutathione
disulfide, and 2-aminoadipate in FATP1-OE. Methionine sulfoxide is a
product of methionine oxidation and is a biomarker of oxidative stress
[79]. Aminoadipic acid (2-aminoadipate) is a lysine breakdown
metabolite that is a biomarker of oxidative stress and predicts diabetes
risk [80e83]. Cysteineglutathione disulfide is a derivative of gluta-
thione and can generate S-glutathionylation, a signaling molecule for
oxidative stress [84]. Furthermore, it is possible that the high iNOS
expression in the absence of Fatp1 reported herein in BMDMs will also
be found in ATMs and would explain the significant increase in520 MOLECULAR METABOLISM 5 (2016) 506e526  2016 The Authors. Published by Elsevier GmbH. Toxidative damage detected in HFD-fed Fatp1B/ adipose, which will
be investigated future studies.
Comprehensive metabolic analysis of FATP1’s effect on MF biology
was undertaken to gain insight into pathways that may lead to elevated
inflammation and/or oxidative stress. Metabolomics analysis revealed
that, as expected, BMDM were not highly metabolically active, with few
metabolites up- or downregulated from unstimulated to the CAM-
activated state. Therefore, in cells with little FA metabolism, it was
difficult to detect a large FATP1-mediated effect. In the absence of
Fatp1, the PPP was upregulated, suggesting that FATP1 normally acts
to limits MF ROS production through the PPP. The PPP is a source of
the NADPH required for iNOS generation of ROS. Another source of
oxidative stress in CAM-activated MFs is the shunting of arginine to
iNOS, which catalyzes the conversion of arginine to NO. AAM-activated
MFs divert arginine instead to arginase-1, which converts arginine to
ornithine. Ornithine, a precursor of collagen synthesis, is necessary for
AAM function in tissue remodeling and wound repair [4]. Thus, in
AAMs, less arginine is directed towards iNOS and, therefore, pro-
duction of ROS and collateral tissue oxidative damage is reduced.
Herein, the combined result of enhanced PPP and iNOS activity in the
absence of Fatp1 is ROS production and oxidative damage to tissues.
Indeed, oxidative damage evident in HFD-exposed adipose from
Fatp1B/ mice further supported metabolic shifts linked to increased
ROS production in the absence of Fatp1. Additionally, one metabolite
greatly regulated by loss of Fatp1 in BMDM was riboflavin (Vitamin B2).
Riboflavin is a central component of the cofactors flavin mono-
nucleotide (FMN) and flavin adenine dinucleotide (FAD) and is neces-
sary for many flavoprotein enzyme reactions including oxidases
including the phagocytic NADPH oxidase 2 (Nox2), Complex I and
Complex II of the electron transport chain, Vitamin B6 and B3 pro-
duction, as well as oxidation of pyruvate, a-ketoglutarate, branched-
chain amino acids, and fatty acids. In addition, reduction of the
oxidized form of glutathione (GSSG) to its reduced form (GSH) by
glutathione reductase is FAD dependent. Thus, a host of metabolically
relevant pathways are regulated by riboflavin. Interestingly, Fatp1
toggled riboflavin concentrations: unstimulated BMDM lacking Fatp1
had almost two-fold greater riboflavin while CAM stimulated Fatp1B/
contained just a third of control levels. In MFs, riboflavin has been
shown to reduce oxidative burst, immune response, and resistance to
infection [85,86]. Taken together, the complex regulation of metabo-
lites such as riboflavin in unstimulated and stimulated states suggests
that detailed time course studies are necessary to fully establish the
contribution of FATP1 to riboflavin-mediated inflammation.
In contrast to BMDM, RAW MFs were very metabolically active with
tens to hundreds of metabolites differentially regulated in the unsti-
mulated or CAM-activated state. RAW cells are an immortalized and
rapidly proliferating cell line, which is reflected in the metabolic profile.
Hence, there were greater Fatp1-dependent differences detected in
the RAW cells compared to BMDM, likely because of needs for
membrane synthesis during proliferation and other processes. RAW
MFs did not express detectable FATP1 protein, which emphasizes the
importance of this model as a gain of function approach. FATP1
overexpression elevated ACSL activity and fatty acid uptake, as well as
the concentration of many fatty acids demonstrating the profound
capacity of this transporter to alter MF lipid composition. Compared to
Fatp1-deficient MFs, the opposite shift in substrate metabolism was
observed in RAW MFs over-expressing FATP1: FATP1 overexpression
suppressed Glut1, glucose uptake, glycolytic rate and capacity, and
glucose oxidation. However, similar to the “mixed” M1/M2 phenotype
commonly detected in vivo, the metabolic phenotype of FATP1-OE
RAW MFs is also a mixture of what was traditionally consideredhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
CAM-like and AAM-like metabolism. We find that, despite a dramatic
down-regulation of glycolysis using bioenergetics analysis, metab-
olomics analysis also revealed decreased intermediates of the TCA
cycle, potentially supporting a more energetic phenotype in that the
cells are relying upon other substrates in oxidative metabolism
[75,87,88]. Detailed flux analysis is warranted to further study the
impact of FATP1 on glycolysis and oxidative metabolism.
In conjunction with reduced glycolysis, CAM-like RAW MFs over-
expressing FATP1 failed to be fully CAM activated: Fatp1 over-
expression reduced CAM-stimulated iNOS, TNFa, IL-6, MCP1 and IL-
1b, while it almost tripled Hmox-1. Metabolomic analysis supported
that FATP1 overexpression blunted induction of iNOS activity in
response to CAM activation as evidenced by more than a 50%
reduction in citrulline and an increase in polyamines and polyamine
associated metabolites (which demonstrated a redirection of arginine
from iNOS metabolism towards arginase-1 metabolism). Hmox-1
catalyzes the degradation of heme, thus protecting against iron-
induced oxidative damage [56] and was reduced in Fatp1/
BMDM. Since RAW MFs are originally derived from viral-induced
mouse leukemia and display a Warburg-like metabolism reminiscent
of the CAM-like phenotype, the inhibition of pro-inflammatory activa-
tion by the metabolic switch induced by FATP1 was striking, although
we did not observe an increase in alternatively activated markers
including Mrc1 or Arg1, reiterating the importance of specific fatty acid
transporters in metabolic reprogramming.
FATP1 is assigned to the “negative regulation of phospholipid
biosynthetic process” gene ontology class based on the study from
Mitchell et al. [89]. Metabolomics data indicated enhanced glycerolipidFigure 6: FATP1 is a novel regulator of immunometabolism: Working Model: Fatt
macrophage (AAM) phenotype, limit oxidative stress, and to reduce high fat diet (HFD)-indu
exacerbates classic macrophage (CAM) activation and HFD-induced metabolic dysfunction
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www.molecularmetabolism.commetabolism in the absence of Fatp1, with increases observed in
ethanolamine, glycerophosphocholine, and CDP-choline in CAM acti-
vated Fatp1/ BMDM. Phospholipids serve as a pool of bioactive
lipids including arachidonic, linoleic, and palmitic acid, which could
modulate MF-mediated inflammation [90]. Therefore, future studies
will determine if FATP1 regulates MF activation via regulation of ratios
of phospholipid classes and/or fatty acid composition within those
classes. Metabolomic evidence demonstrated potent regulation of long
chain fatty acids arachidonate and linoleate, sources of bioactive lipid
mediators including eicosanoids. Eicosanoids have stimulatory and
inhibitory effects, are short-lived, and are often further metabolized to
lipid mediators that may have activities far extending the precursor.
FATP1 overexpression greatly decreased availability of one of the main
eicosanoid precursors, free arachidonate, to almost undetectable
levels. In line with altered substrate availability, FATP1 overexpression
greatly reduced arachidonate-derived HETE metabolites and some
linoleate-derived eicosanoids such as 9,10-DHOME. 15-HETE was
increased in Fatp1/ BMDM, supporting a critical reciprocal role for
FATP1 gain and loss of activity in some eicosanoid production. HETEs
are formed by the 5-, 12- and 15-lipoxygenase (LO) pathways. 5- and
12-LO products are mainly pro-inflammatory [91], whereas the main
15-LO product 15-HETE has anti-inflammatory capacities, although
evidence exists that 15-HETE also induces ROS production [92].
Interestingly, the diol 9,10-diHOME is implicated as a cytotoxic agent
[93]. Importantly, oxidation of many eicosanoids is an NAD þ -
dependent process (e.g. 15-hydroxyprostaglandin dehydrogenase),
thus the production of eicosanoids is directly responsive to mito-
chondrial metabolism. Furthermore, one lipid-derived metabolitey acid transport protein (FATP1) is necessary to maintain the alternatively activated
ced adipose tissue inflammation and systemic glucose intolerance. Deficiency of Fatp1
.
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PPARg agonist derived from linoleic acid [94]. Activation of PPARg is
well-known to reduce inflammation and could be a potential mecha-
nism through which FATP1 may function to limit inflammation. Thus,
FATP1 may regulate ROS and inflammation through activation of long
chain fatty acid precursors to modulate production of eicosanoids,
combined with modulation of mitochondrial metabolism. While an
attempt was made to measure eicosanoids in white adipose tissue,
any MF-specific effects were surely masked by the sheer lipid mass of
the tissue. Therefore, ATM-specific eicosanoid analysis is necessary.
Further radiotracer, flux analysis, and inhibitor or loss-of-function
studies are also necessary to fully comprehend the complexity of
FATP1’s role in lipid mediator biology.
Finally, we have begun to examine FATP1’s effects in a translational
approach. Fatp1 contains genetic variants (i.e. single nucleotide
polymorphisms, SNPs) associated with diabetes or risk factors for
diabetes [95,96]. Variants located in and near FATP1 were detected
that were associated with FATP1 expression in human adipose tissue.
Fatp1 is upregulated by adiponectin, PPARg, and the orphan receptor
TR4, therefore, the interaction between variants and transcriptional
regulation of Fatp1 expression should be further studied. While
encouraging, these findings were detected at the tissue level in total
subcutaneous adipose tissue. Hence, it was impossible to take into
account the complexity of the cellular composition of the adipose
microenvironment and effects specifically on ATMs. Indeed, few large
population genetic studies focus solely on monocyte/MFs and future
genetic analysis of this immune population is of great interest.
5. CONCLUSION
In summary, integrating loss- and gain-of-function models, we report
for the first time that MF FATP1 is necessary to elicit the AAM
phenotype in vitro and controls MV activation and adipose inflam-
mation in vivo (see model in Figure 6). We present mechanistic insight
into the relationship between FATP1 and inflammation, a previously
unrecognized regulator of MF substrate metabolism and inflamma-
tion. MFs are an extremely heterogeneous population of cells whose
capacity for metabolic flexibility has important implications for local
and systemic responses to diet and other insults. Our investigation into
preferential metabolic substrate usage by MFs has demonstrated that
FATP1 is a novel regulator of immunometabolism. While this project
focused on metabolic changes in the macrophage and the resulting
in vitro and in vivo consequences, there are many questions left
unanswered including FATP1’s role in phagocytosis, antigen presen-
tation, motility, as well as interactions with other key cells such as T
cells important to metabolic diseases.
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